Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Series A round by Biohaven brings in $80mm for CNS pipeline development; later adds $20mm

Executive Summary

Biohaven Pharmaceuticals Holding Co. Ltd. (orphan neurologic disease candidates) raised $80mm in a Series A preferred round led by Venrock, which was joined by RA Capital Management, Vivo Capital, Aisling Capital, Rock Springs Capital, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations, Litmore Capital, and board members John W. Childs and Greg Bailey, MD (who is also the company’s SVP, business development). Cowen & Co. and William Blair were co-placement agents. Prior to this round, the company brought in about $20mm in financing.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Therapeutic Drug Monitoring
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register